Cargando…

Home intravenous antibiotic treatment for intractable cholangitis in patients with biliary atresia following Kasai portoenterostomies

PURPOSE: Patients with biliary atresia (BA) treated with Kasai portoenterostomy may later develop intractable cholangitis (IC) that is unresponsive to routine conservative treatment. It may cause biliary cirrhosis and eventually hepatic failure with portal hypertension. Control of IC requires prolon...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Jae Ho, Chang, Eun Young, Chang, Hye Kyung, Kim, Seong Min, Han, Seok Joo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Surgical Society 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3204694/
https://www.ncbi.nlm.nih.gov/pubmed/22066060
http://dx.doi.org/10.4174/jkss.2011.80.5.355
_version_ 1782215250377965568
author Shin, Jae Ho
Chang, Eun Young
Chang, Hye Kyung
Kim, Seong Min
Han, Seok Joo
author_facet Shin, Jae Ho
Chang, Eun Young
Chang, Hye Kyung
Kim, Seong Min
Han, Seok Joo
author_sort Shin, Jae Ho
collection PubMed
description PURPOSE: Patients with biliary atresia (BA) treated with Kasai portoenterostomy may later develop intractable cholangitis (IC) that is unresponsive to routine conservative treatment. It may cause biliary cirrhosis and eventually hepatic failure with portal hypertension. Control of IC requires prolonged hospitalization for the administration of intravenous antibiotics. To reduce the hospitalization period, we designed a home intravenous antibiotic treatment (HIVA) which can be administered after initial inpatient treatment. In this study, we reviewed the effects of this treatment. METHODS: We reviewed medical records of 10 patients treated with HIVA for IC after successful Kasai portoenterostomies performed for BA between July 1997 and June 2009. RESULTS: The duration of HIVA ranged from 8 to 39 months (median, 13.5 months). The median length of hospital stay was 5.7 days per month for conventional treatments to manage IC before HIVA and, 1.5 days per month (P = 0.012) after HIVA. The median amount of medical expenses per month was reduced by about one tenth with HIVA. One patient underwent liver transplantation due to uncontrolled esophageal variceal bleeding, but the other nine patients had acceptable hepatic function with native livers. CONCLUSION: HIVA may be an effective primary treatment for IC after Kasai portoenterostomies for BA, and reduce length of hospital stay and medical expense.
format Online
Article
Text
id pubmed-3204694
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher The Korean Surgical Society
record_format MEDLINE/PubMed
spelling pubmed-32046942011-11-07 Home intravenous antibiotic treatment for intractable cholangitis in patients with biliary atresia following Kasai portoenterostomies Shin, Jae Ho Chang, Eun Young Chang, Hye Kyung Kim, Seong Min Han, Seok Joo J Korean Surg Soc Original Article PURPOSE: Patients with biliary atresia (BA) treated with Kasai portoenterostomy may later develop intractable cholangitis (IC) that is unresponsive to routine conservative treatment. It may cause biliary cirrhosis and eventually hepatic failure with portal hypertension. Control of IC requires prolonged hospitalization for the administration of intravenous antibiotics. To reduce the hospitalization period, we designed a home intravenous antibiotic treatment (HIVA) which can be administered after initial inpatient treatment. In this study, we reviewed the effects of this treatment. METHODS: We reviewed medical records of 10 patients treated with HIVA for IC after successful Kasai portoenterostomies performed for BA between July 1997 and June 2009. RESULTS: The duration of HIVA ranged from 8 to 39 months (median, 13.5 months). The median length of hospital stay was 5.7 days per month for conventional treatments to manage IC before HIVA and, 1.5 days per month (P = 0.012) after HIVA. The median amount of medical expenses per month was reduced by about one tenth with HIVA. One patient underwent liver transplantation due to uncontrolled esophageal variceal bleeding, but the other nine patients had acceptable hepatic function with native livers. CONCLUSION: HIVA may be an effective primary treatment for IC after Kasai portoenterostomies for BA, and reduce length of hospital stay and medical expense. The Korean Surgical Society 2011-05 2011-05-06 /pmc/articles/PMC3204694/ /pubmed/22066060 http://dx.doi.org/10.4174/jkss.2011.80.5.355 Text en Copyright © 2011, the Korean Surgical Society http://creativecommons.org/licenses/by-nc/3.0 Journal of the Korean Surgical Society is an Open Access Journal. All articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Shin, Jae Ho
Chang, Eun Young
Chang, Hye Kyung
Kim, Seong Min
Han, Seok Joo
Home intravenous antibiotic treatment for intractable cholangitis in patients with biliary atresia following Kasai portoenterostomies
title Home intravenous antibiotic treatment for intractable cholangitis in patients with biliary atresia following Kasai portoenterostomies
title_full Home intravenous antibiotic treatment for intractable cholangitis in patients with biliary atresia following Kasai portoenterostomies
title_fullStr Home intravenous antibiotic treatment for intractable cholangitis in patients with biliary atresia following Kasai portoenterostomies
title_full_unstemmed Home intravenous antibiotic treatment for intractable cholangitis in patients with biliary atresia following Kasai portoenterostomies
title_short Home intravenous antibiotic treatment for intractable cholangitis in patients with biliary atresia following Kasai portoenterostomies
title_sort home intravenous antibiotic treatment for intractable cholangitis in patients with biliary atresia following kasai portoenterostomies
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3204694/
https://www.ncbi.nlm.nih.gov/pubmed/22066060
http://dx.doi.org/10.4174/jkss.2011.80.5.355
work_keys_str_mv AT shinjaeho homeintravenousantibiotictreatmentforintractablecholangitisinpatientswithbiliaryatresiafollowingkasaiportoenterostomies
AT changeunyoung homeintravenousantibiotictreatmentforintractablecholangitisinpatientswithbiliaryatresiafollowingkasaiportoenterostomies
AT changhyekyung homeintravenousantibiotictreatmentforintractablecholangitisinpatientswithbiliaryatresiafollowingkasaiportoenterostomies
AT kimseongmin homeintravenousantibiotictreatmentforintractablecholangitisinpatientswithbiliaryatresiafollowingkasaiportoenterostomies
AT hanseokjoo homeintravenousantibiotictreatmentforintractablecholangitisinpatientswithbiliaryatresiafollowingkasaiportoenterostomies